-
Mashup Score: 22Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian - 1 day(s) ago
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis - Beyond the Abstract - 6 day(s) ago
non-muscle invasive bladder cancer (NMIBC), transurethral resection of the bladder tumor (TURBT), Tumor T stage, cancer-specific survival (CSS) in patients with non-muscle invasive bladder cancer (NMIBC).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 3
Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Navigating #NMIBC risk stratification and treatment. Neal Shore @CURCMB joins @UroDocAsh @MDAndersonNews to discuss the crucial role of the @AmerUrological guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > https://t.co/dB8GTF878o https://t.co/ZTPe2rGba6
-
-
Mashup Score: 2Implementing Nadofaragene Firadenovec Treatment in NMIBC - Mark Tyson, Aimee Boden, & Meghann Davis - 19 day(s) ago
Zachary Klaassen hosts Mark Tyson, Aimee Boden, and Meghann Davis, to discuss the implementation of Adstiladrin treatment in the clinic setting. They discuss the logistics of offering this FDA approved based on the phase III trial demonstrating significant efficacy in BCG-unresponsive non-muscle invasive bladder cancer. The team at Mayo Clinic began administering Adstiladrin in late November…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Implementing nadofaragene firadenovec treatment in #NMIBC. @MarkTysonMD, Aimee Boden, & Meghann Davis @MayoClinic join @zklaassen_md @GACancerCenter to discuss implementation and logistics and the importance of a comprehensive and collaborative approach > https://t.co/uAvI7jvZrZ https://t.co/XIVCIgK9YE
-
-
Mashup Score: 22Intravesical Nadofaragene Firadenovec Gene Therapy for BCG-Unresponsive NMIBC - Stephen Boorjian - 1 month(s) ago
Stephen Boorjian discusses rAd-IFNα (nadofaragene firadenovec), a novel intravesical therapy for BCG-unresponsive non-muscle-invasive bladder cancer. Developed with Dr. Colin Dinney, rAd-IFNα is an adenoviral vector combined with Syn 3, turning the bladder into an interferon bioreactor. The phase three trial showed a 53% complete response rate in patients with carcinoma in situ. Secondary…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 7An Analysis in NMIBC Patients - A Comparative Study of White Light and Blue Light Cystoscopy in an Equal Access Setting - Stephen B. Williams - 1 month(s) ago
Stephen Williams discusses the evolving role of blue light cystoscopy in detecting non-muscle invasive bladder cancer (NMIBC). The conversation covers its pathophysiology, diagnostic and surveillance applications, emphasizing selective utilization and benefits post-BCG therapy. Dr. Williams references a study in Clinical Genitourinary Cancer, sharing insights from a study comparing blue and…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet
-
Mashup Score: 3
Ashish Kamat and Morgan Rouprêt explore advancements in non-muscle-invasive bladder cancer (NMIBC) treatments. Professor Rouprêt emphasizes two NMIBC categories: high-grade disease, where muscle-invasive and high-grade bladder cancer lines blur, and low-grade disease, where de-intensification of follow-up and treatment is sought. He highlights the THOR-2 cohort presented by Jim Catto at ESMO,…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 0Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis - Beyond the Abstract - 1 month(s) ago
non-muscle invasive bladder cancer (NMIBC), transurethral resection of the bladder tumor (TURBT), Tumor T stage, cancer-specific survival (CSS) in patients with non-muscle invasive bladder cancer (NMIBC).
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 1Navigating NMIBC Risk Stratification and Treatment - Neal Shore - 1 month(s) ago
Ashish Kamat is joined by Neal Shore to delve into risk stratification in non-muscle invasive bladder cancer (NMIBC). Dr. Shore highlights the crucial role of the AUA guidelines, developed with significant contributions from Dr. Kamat and others, in differentiating patients into low, intermediate, and high-risk categories. This stratification informs the frequency of cystoscopies, the intensity…
Source: www.urotoday.comCategories: General Medicine News, UrologyTweet-
Navigating #NMIBC risk stratification and treatment. Neal Shore @CURCMB joins @UroDocAsh @MDAndersonNews to discuss the crucial role of the @AmerUrological guidelines, developed with significant contributions from Dr. Kamat and other leaders in the field > https://t.co/dB8GTF878o https://t.co/ZTPe2rGba6
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive #NMIBC. @SBoorjian @MayoClinic joins @UroDocAsh @MDAndersonNews to discuss this novel therapy, nuances and updated trial results, in a conversation on UroToday > https://t.co/NTlBWrrmLq https://t.co/H6aqecjSGv